Clinical Trial Update: Long Term Follow-up Study of Type-1 Gaucher Subjects Post FLT201 Dose (GALILEO-2) [Phase 1, Phase 2]

View source ↗

Summary

Long-term follow-up GALILEO-2 study of FLT201 in Gaucher disease type 1 is a Phase 1/2 trial sponsored by Spur Therapeutics, with status listed as active, not r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gaucher Disease Type

Drugs mentioned

• FLT201

Snippet

Sponsor: Spur Therapeutics | Conditions: Gaucher Disease, Type 1 | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING